Trial Profile
A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant network
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms Blinatumomab in infant ALL
- 27 Apr 2023 Results assessing safety and efficacy of blinatumomab, a bispecific T-cell engager molecule targeting CD19, in infants with KMT2A-rearranged ALL published in the New England Journal of Medicine
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 29 Oct 2021 Planned End Date changed from 17 Oct 2022 to 31 Jan 2024.